|
ZBTB24 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.34720000044553E-07 |
| Normal-vs-Stage3 |
4.44089209850063E-15 |
| Normal-vs-Stage4 |
1.6503465261053E-12 |
| Stage1-vs-Stage2 |
1.719970E-01 |
| Stage1-vs-Stage3 |
8.145600E-01 |
| Stage1-vs-Stage4 |
1.345560E-01 |
| Stage2-vs-Stage3 |
1.728960E-01 |
| Stage2-vs-Stage4 |
4.057900E-02 |
| Stage3-vs-Stage4 |
2.974600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.26640000006762E-07 |
| Normal-vs-Asian |
4.58189042262802E-13 |
| Caucasian-vs-AfricanAmerican |
3.938600E-01 |
| Caucasian-vs-Asian |
6.962400E-01 |
| AfricanAmerican-vs-Asian |
2.534000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.30384592011978E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.809400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
4.94737584233462E-12 |
| Normal-vs-Age(81-100Yrs) |
2.401200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.566800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.656200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.888800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.492800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.812000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.946600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.587800E-02 |
| Classical-VS-Follicular |
9.068600E-01 |
| Classical-VS-Other |
2.523400E-01 |
| Classical-VS-Normal |
4.36350955368425E-12 |
| Tall-VS-Follicular |
9.574000E-02 |
| Tall-VS-Other |
7.896400E-01 |
| Tall-VS-Normal |
4.19864143452742E-12 |
| Follicular-VS-Other |
3.324800E-01 |
| Follicular-VS-Normal |
6.81970035998347E-11 |
| Other-VS-Normal |
1.032620E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
5.55111512312578E-16 |
| N0-vs-N1 |
2.140300E-02 |
|
|
